Free Trial
OTCMKTS:CHGCY

Chugai Pharmaceutical 10/25/2024 Earnings Report

Chugai Pharmaceutical logo
$29.81 +0.83 (+2.86%)
As of 05/2/2025 03:59 PM Eastern

Chugai Pharmaceutical EPS Results

Actual EPS
$0.22
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Chugai Pharmaceutical Revenue Results

Actual Revenue
$2.12 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Chugai Pharmaceutical Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Chugai Pharmaceutical's next earnings date is estimated for Thursday, July 24, 2025, based on past reporting schedules.

Conference Call Resources

Chugai Pharmaceutical Earnings Headlines

Jefferies Keeps Their Hold Rating on Chugai Pharmaceutical Co (CHGCF)
Bernstein Remains a Buy on Chugai Pharmaceutical Co (CHGCF)
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Chugai Pharmaceutical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Chugai Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chugai Pharmaceutical and other key companies, straight to your email.

About Chugai Pharmaceutical

Chugai Pharmaceutical (OTCMKTS:CHGCY) Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

View Chugai Pharmaceutical Profile

More Earnings Resources from MarketBeat